~67 spots leftby Apr 2026

Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)

(ADMIRE-CD-II Trial)

Recruiting in Palo Alto (17 mi)
+158 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: Tigenix S.A.U.
Pivotal Trial (Near Approval)
Prior Safety Data

Trial Summary

What is the purpose of this trial?

The purpose of this study is to evaluate the combined remission of complex perianal fistulas, defined as the clinical assessment at Week 24 of closure of all treated external openings that were draining at baseline despite gentle finger compression, and absence of collections greater than (\>) 2 centimeter (cm) (in at least 2 dimensions) confirmed by blinded central magnetic resonance imaging (MRI) assessment at Week 24.

Research Team

SD

Study Director

Principal Investigator

Takeda

Eligibility Criteria

Inclusion Criteria

Signed informed consent
Participants of either gender >= 18 years and <= 75 years of age
Participants with CD diagnosed at least 6 months prior to Screening visit
See 20 more

Exclusion Criteria

Congenital or acquired immunodeficiencies, including participants known to be HIV carriers
Severe trauma within 6 months prior to Screening visit
Participants who do not wish to or cannot comply with study procedures
See 21 more

Treatment Details

Interventions

  • Cx601 (Stem Cell Therapy)
  • Placebo (Other)
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Cx601Experimental Treatment1 Intervention
Cx601 expanded adipose-derived stem cells (eASCs) 120 million cells (5 million cells per mL) was administered once by local injection.
Group II: PlaceboPlacebo Group1 Intervention
Placebo (saline) 24 milliliters (mL) was administered once by local injection.

Find a Clinic Near You

Research Locations NearbySelect from list below to view details:
Digestive Health Center of LouisianaBaton Rouge, LA
University of Nevada School of MedicineLas Vegas, NV
North Shore University Hospital - GastroenterologyManhasset, NY
Carle Foundation HospitalUrbana, IL
More Trial Locations
Loading ...

Who Is Running the Clinical Trial?

Tigenix S.A.U.

Lead Sponsor

Trials
11
Patients Recruited
1,500+